Cryoport (CYRX) Stock Overview
Provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CYRX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
Cryoport, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.68 |
| 52 Week High | US$10.46 |
| 52 Week Low | US$4.58 |
| Beta | 1.61 |
| 1 Month Change | -6.47% |
| 3 Month Change | 32.78% |
| 1 Year Change | 22.69% |
| 3 Year Change | -61.63% |
| 5 Year Change | -80.27% |
| Change since IPO | -91.28% |
Recent News & Updates
Recent updates
Improved Revenues Required Before Cryoport, Inc. (NASDAQ:CYRX) Shares Find Their Feet
Jul 22
Most Shareholders Will Probably Find That The Compensation For Cryoport, Inc.'s (NASDAQ:CYRX) CEO Is Reasonable
May 30Cryoport (NASDAQ:CYRX) Has Debt But No Earnings; Should You Worry?
Apr 09
New IntegriCell And CXHV3 Systems Will Improve Cell Therapy Supply
Rapid expansion in Life Sciences Services and support for cell and gene therapies are key drivers of Cryoport's revenue growth.Cryoport, Inc. (NASDAQ:CYRX) Just Reported Earnings, And Analysts Cut Their Target Price
Mar 06Market Cool On Cryoport, Inc.'s (NASDAQ:CYRX) Revenues Pushing Shares 25% Lower
Feb 22Investors Continue Waiting On Sidelines For Cryoport, Inc. (NASDAQ:CYRX)
Dec 03Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Nov 06The Market Lifts Cryoport, Inc. (NASDAQ:CYRX) Shares 36% But It Can Do More
Aug 09Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Jul 22Slammed 28% Cryoport, Inc. (NASDAQ:CYRX) Screens Well Here But There Might Be A Catch
Jun 25Potential Upside For Cryoport, Inc. (NASDAQ:CYRX) Not Without Risk
Apr 15Cryoport, Inc. (NASDAQ:CYRX) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
Mar 15Cryoport Tanks On Chilling Results And Bad Decisions
Mar 14Is Cryoport (NASDAQ:CYRX) Using Debt In A Risky Way?
Mar 10Fewer Investors Than Expected Jumping On Cryoport, Inc. (NASDAQ:CYRX)
Jan 15Health Check: How Prudently Does Cryoport (NASDAQ:CYRX) Use Debt?
Oct 06Downgrade: Here's How Analysts See Cryoport, Inc. (NASDAQ:CYRX) Performing In The Near Term
Jul 23Cryoport, Inc.'s (NASDAQ:CYRX) Subdued P/S Might Signal An Opportunity
Jul 12Is Cryoport (NASDAQ:CYRX) A Risky Investment?
Jun 13Cryoport, Inc.'s (NASDAQ:CYRX) Intrinsic Value Is Potentially 96% Above Its Share Price
Mar 06Shareholder Returns
| CYRX | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 5.2% | 15.0% | 1.2% |
| 1Y | 22.7% | -12.1% | 17.9% |
Return vs Industry: CYRX exceeded the US Life Sciences industry which returned -12.1% over the past year.
Return vs Market: CYRX exceeded the US Market which returned 17.9% over the past year.
Price Volatility
| CYRX volatility | |
|---|---|
| CYRX Average Weekly Movement | 13.0% |
| Life Sciences Industry Average Movement | 8.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: CYRX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CYRX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 1,098 | Jerry Shelton | www.cryoportinc.com |
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company’s Life Sciences Services segment provides temperature-controlled logistics and cryogenic biostorage within the life science industry. Its Life Sciences Products segment offers cryogenic freezers, cryogenic dewars, and accessories within the life science industry through direct sales or a distribution network.
Cryoport, Inc. Fundamentals Summary
| CYRX fundamental statistics | |
|---|---|
| Market cap | US$484.65m |
| Earnings (TTM) | -US$50.05m |
| Revenue (TTM) | US$237.88m |
Is CYRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CYRX income statement (TTM) | |
|---|---|
| Revenue | US$237.88m |
| Cost of Revenue | US$130.96m |
| Gross Profit | US$106.92m |
| Other Expenses | US$156.98m |
| Earnings | -US$50.05m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 44.95% |
| Net Profit Margin | -21.04% |
| Debt/Equity Ratio | 36.1% |
How did CYRX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/05 01:48 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cryoport, Inc. is covered by 17 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yuan Zhi | B. Riley Securities, Inc. |
| Andrew D'Silva | B. Riley Securities, Inc. |
| David Larsen | BTIG |